Inside Precision Medicine September 20, 2024
RNA editing can create novel protein modifications, which the partnership hopes will unlock “undruggable” chronic diseases
At one end of the drug development table are people like Uli Stilz, PhD, a former vice president at Novo Nordisk and founder of the Danish company’s Bio Innovation Hub in Boston. Stilz has worked on several drugs for various conditions and modalities. Novo Nordisk has many tools at its disposal, including small molecules, siRNAs, antibodies, cell therapies, and more. However, the global health company still lacks the key to unlocking the mysteries of cardiometabolic diseases.
“How can we develop new therapeutics with transformative potential that are not accessible or where the biology would be locked?” Stilz told Inside Precision Medicine. “We want to...
Today's Sponsors
Today's Sponsor